Table 1.
The clinicopathologic characteristics of all patients
| Characteristic | RSCC | LSCRC | P value |
|---|---|---|---|
| Sex | 0.107 | ||
| Male | 30 (60%) | 104 (72.2) | |
| Female | 20 (40%) | 40 (28.8) | |
| Age | 55.50 (23–75) | 60 (20–75) | 0.311 |
| Liver metastasis | 0.293 | ||
| Single lesion | 8 (16%) | 15 (10.4) | |
| Multiple lesions | 42 (84%) | 129 (89.6) | |
| Diameter of liver metastasis | 0.644 | ||
| <3 cm | 20 (40%) | 63 (43.8%) | |
| ≥3 cm | 30 (60%) | 81 (56.2%) | |
| CEA (ng/ml) | 0.646 | ||
| <200 | 40 (80%) | 105 (72.9%) | |
| ≥200 | 10 (20%) | 39 (27.1%) | |
| CA199 (U/ml) | 0.644 | ||
| <35 | 20 (40%) | 63 (43.8%) | |
| ≥35 | 30 (60%) | 81 (56.2%) | |
| Systemic chemotherapy | 0.194 | ||
| No | 10 (20) | 18 (5.6%) | |
| Yes | 40 (80) | 126 (94.4%) | |
| Target agent | 0.970 | ||
| None | 39 (78%) | 109 (75.7%) | |
| C225 | 5 (10%) | 12 (8.3%) | |
| Avastin | 4 (8%) | 15 (10.4%) | |
| Both | 1 (2%) | 4 (2.8%) | |
| Other | 1 (2%) | 4 (2.8%) |
Data are presented as number (percentage) or mean (range)
RSCC right-side colon cancer, LSCRC left-side colorectal cancer, CEA carcinoembryonic antigen, CA cancer antigen